Top 5 videos, podcasts & graphics on Outsourcing-Pharma

By Nick Taylor

- Last updated on GMT

Outsourcing-Pharma presents five of our top audio-visual articles of 2010, including a timeline of Lilly’s outsourcing, the need for US capacity and why biomarkers are indispensible.

Over the past 12 months Outsourcing-Pharma has continued to lead the field in use of innovative online content, such as videos, audio podcasts and interactive visualisations. Below we round-up five of the most viewed audio-visual articles of 2010.

Timeline of Lilly’s outsourcing

In March we published an interactive timeline of outsourcing deals inked by Eli Lilly to show the expansive approach taken by the big pharma since committing to increased use of service providers.

Since publication of the timeline Lilly has continued to outsource operations. In September Parexel partnered with Lilly to support clinical development programmes in Asia Pacific. Furthermore, Clearstone began providing services to Lilly from its site in Beijing, China.

Biomarkers “indispensible” in cancer drug development, says Quintiles

In this podcast Christopher Ung, vice president (VP) of strategic business and oncology operations at Quintiles, said the insight gained from biomarkers makes them vital in cancer drug development.

Biomarker use gives efficacy data earlier in development, said Ung, and using this to make more informed decisions can cut trial costs and duration. Development of new technologies and models will continue, said Ung, and help the industry in efforts to combat cancer.

A decade of animal safety and efficacy testing – visualised

Using data showing every animal used in safety and efficacy testing in Great Britain Outsourcing-Pharma created a highly interactive visualisation. The tool allows users to drill down from a 10 year overview to find out, for instance, how many cats were used in efficacy testing in 2002.

A 13 per cent drop in 2009 ended several years of increases in the number of animals used in pharma safety and efficacy testing in Great Britain. This drop, and the other ups and downs of the past decade, is displayed in the interactive visualisation.

US presence is a must for biologics producers, says Recipharm

Thomas Eldered, CEO of Recipharm, spoke to Outsourcing-Pharma about the launch of RecipharmCobra Biologics (RCB) and the importance of the US in this podcast from March.

Recipharm acquired Cobra for its biologics manufacturing capabilities and US presence it maintains through a commercial office in Chicago, Illinois, US.

PRA unveils new US bioanalytical lab at AAPS

At AAPS 2010 PRA International held an event to reveal it had opened a bioanalytical services laboratory in Lenexa, Kansas, US. Outsourcing-Pharma was at the event and had a video discussing the development recorded, edited and online within hours of the news breaking.

In the video Peter Ketelaar, VP of bioanalytical labs at PRA, said proximity to the company’s pharmacology facility would improve logistics, sample integrity and turnaround time.

Related topics Markets & regulatory news

Related news

Show more

Follow us

Products

View more

Webinars